RxDoctor Payments Data

Jacqueline Cox, MD

Hematology & Oncology · Fairbanks, AKNPI 1538153564

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations.

$517in general payments, 2019–2025

Across 24 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$99
  • Genentech USA, Inc.$77
  • E.r. Squibb & Sons, L.L.C.$48
  • Johnson & Johnson$47
  • Foundation Medicine, Inc.$27
  • Amgen$26
  • plus $193 from 10 others

What the payments were for

  • Food & beverage$46690%
  • Education$5210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few hematology & oncology providers in Alaskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$965,748
Medicare patients
326
Services billed
54,546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate24$453,909
RevlimidLenalidomide16$281,820
ImbruvicaIbrutinib14$259,322
Lenalidomide20$228,787
IbrancePalbociclib13$203,616
ErleadaApalutamide13$196,145
VenclextaVenetoclax11$114,480
Imatinib Mesylate24$65,667
Exemestane33$8,967
Anastrozole121$3,950
Letrozole63$2,238
Prochlorperazine Maleate41$816
Acyclovir40$464
Hydroxyurea18$428
Dexamethasone20$331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$23$453,90924 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$18$259,32214 claims
Johnson & JohnsonErleada$47$196,14513 claims
AbbVieVenclexta$26$114,48011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology & oncology providers in Alaskaon file to place this against a meaningful peer group, so we don't.

Other hematology & oncology in Fairbanks

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →